

February 19, 2026

SymBio Pharmaceuticals Limited  
 Fuminori Yoshida  
 Representative Director,  
 President and Chief Executive Officer

**Completion, Monthly Exercise Status and Large Volume Exercise of the 65th Stock Acquisition Rights  
 (with Exercise Price Adjustment Clause) Issued through Third-Party Allotment**

SymBio Pharmaceuticals Limited hereby announces the monthly exercise status for February 2026 and the large volume exercise of the 65th Stock Acquisition Rights during the period from February 1 to February 18, 2026, as below., which were allotted to EVO FUND and issued on August 12, 2025 (collectively or individually referred to as the "Stock Acquisition Rights"), and that the exercise of all 65th stock acquisition rights issued was completed yesterday.

**1. Monthly Exercise Status**

1. Name of Stock Acquisition Rights	SymBio Pharmaceuticals Limited's 65th Stock Acquisition Rights		
2. Number of Shares Delivered in the Relevant Month	4,810,000 shares		
3. Number of Stock Acquisition Rights Exercised in the Relevant Month, and Ratio of Exercised to Total Issued Stock Acquisition Rights	48,100 rights (Ratio to total number of Stock Acquisition Rights issued 200,000: 24.1%)		
4. Number of Unexercised Stock Acquisition Rights as of the end of the previous month	48,100 rights		
5. Number of Unexercised Stock Acquisition Rights as of the End of the Relevant Month	0 rights		

\* The ratio of exercised to total issued Stock Acquisition Rights is rounded to one decimal place.

**2. Exercise Status in the Relevant Month**

Exercise Date	Number of Shares Delivered		Exercise Price (Yen)	Number of Stock Acquisition Rights Exercised (Rights)
	Newly Issued Shares	Transferred Treasury Shares		
February 2 (Mon)	50,000	—	86	500
February 3 (Tue)	50,000	—	86	500
February 4 (Wed)	—	—	87	—
February 5 (Thu)	—	—	87	—
February 6 (Fri)	—	—	86	—
February 9 (Mon)	50,000	—	86	500
February 10 (Tue)	500,000	—	86	5,000
February 12 (Thu)	700,000	—	86	7,000
February 13 (Fri)	—	—	87	—

February 16 (Mon)	—	—	87	—
February 17 (Tue)	200,000	—	88	2,000
February 18 (Wed)	3,260,000	—	88	32,600

\* Number of shares issued as of the end of the previous month: 64,079,030 shares (including 90,965 treasury shares)

3. Status of Exercise Restrictions (Status of Compliance with Exercise Restrictions under Article 434 of the Listing Regulations)

(i) Total Number of Shares Delivered (All Series Combined)	(ii) Number of Listed Shares as of Payment Date of Issuance	(iii) Exercise Ratio Subject to Exercise Restrictions ((i) / (ii))
4,810,000 shares	48,855,455 shares	9.8%

\* The exercise ratio subject to exercise restrictions is rounded to one decimal place.

The 58th Stock Acquisition Rights are not exercised during the period from February 1 to February 18, 2026. For further details regarding these Stock Acquisition Rights, please refer to the "Notice Concerning the Treatment of the 58th Stock Acquisition Rights in Light of the Issuance of the 65th to 67th Stock Acquisition Rights" announced on July 22, 2025, and the "Notice Regarding the Issuance of the 65th to 67th Stock Acquisition Rights (with Exercise Price Adjustment Clauses) through Third-Party Allotment and the Execution of a Purchase Agreement (Commit Issue) for the 1st Unsecured Straight Bonds and Stock Acquisition Rights" announced on July 22, 2025.